These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 3354621)

  • 61. Prenatal diagnosis of Canavan disease.
    Matalon R; Michals K; Gashkoff P; Kaul R
    J Inherit Metab Dis; 1992; 15(3):392-4. PubMed ID: 1405477
    [No Abstract]   [Full Text] [Related]  

  • 62. Canavan disease and the role of N-acetylaspartate in myelin synthesis.
    Namboodiri AM; Peethambaran A; Mathew R; Sambhu PA; Hershfield J; Moffett JR; Madhavarao CN
    Mol Cell Endocrinol; 2006 Jun; 252(1-2):216-23. PubMed ID: 16647192
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Identification of the zinc binding ligands and the catalytic residue in human aspartoacylase, an enzyme involved in Canavan disease.
    Herga S; Berrin JG; Perrier J; Puigserver A; Giardina T
    FEBS Lett; 2006 Oct; 580(25):5899-904. PubMed ID: 17027983
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Molecular basis of Canavan's disease: from human to mouse.
    Surendran S; Matalon KM; Tyring SK; Matalon R
    J Child Neurol; 2003 Sep; 18(9):604-10. PubMed ID: 14572138
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Structure of aspartoacylase, the brain enzyme impaired in Canavan disease.
    Bitto E; Bingman CA; Wesenberg GE; McCoy JG; Phillips GN
    Proc Natl Acad Sci U S A; 2007 Jan; 104(2):456-61. PubMed ID: 17194761
    [TBL] [Abstract][Full Text] [Related]  

  • 66. A case of Canavan disease with microcephaly.
    Gowda VK; Bhat MD; Srinivasan VM; Prasad C; Benakappa A; Faruq M
    Brain Dev; 2016 Sep; 38(8):759-62. PubMed ID: 26992473
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Case 15-1998: elevated N-acetylaspartic acid activity in Canavan's disease.
    Breslau J
    N Engl J Med; 1998 Aug; 339(9):636. PubMed ID: 9722443
    [No Abstract]   [Full Text] [Related]  

  • 68. Stable isotope dilution analysis of N-acetylaspartic acid in urine by liquid chromatography electrospray ionization tandem mass spectrometry.
    Al-Dirbashi OY; Rashed MS; Al-Mokhadab MA; Al-Qahtani K; Al-Sayed MA; Kurdi W
    Biomed Chromatogr; 2007 Sep; 21(9):898-902. PubMed ID: 17441217
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Homozygosity for mutation G212A of the gene for aspartoacylase is associated with atypical form of Canavan's disease.
    Velinov M; Zellers N; Styles J; Wisniewski K
    Clin Genet; 2008 Mar; 73(3):288-9. PubMed ID: 18070137
    [No Abstract]   [Full Text] [Related]  

  • 70. Upregulation of N-acetylaspartic acid induces oxidative stress to contribute in disease pathophysiology.
    Surendran S; Bhatnagar M
    Int J Neurosci; 2011 Jun; 121(6):305-9. PubMed ID: 21348802
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Canavan disease: findings in four new cases.
    Michelakakis H; Giouroukos S; Divry P; Katsarou E; Rolland MO; Skardoutsou A
    J Inherit Metab Dis; 1991; 14(2):267-8. PubMed ID: 1886410
    [No Abstract]   [Full Text] [Related]  

  • 72. Aspartoacylase gene knockout results in severe vacuolation in the white matter and gray matter of the spinal cord in the mouse.
    Surendran S; Campbell GA; Tyring SK; Matalon R
    Neurobiol Dis; 2005 Mar; 18(2):385-9. PubMed ID: 15686967
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Expression of aspartoacylase activity in cultured rat macroglial cells is limited to oligodendrocytes.
    Baslow MH; Suckow RF; Sapirstein V; Hungund BL
    J Mol Neurosci; 1999; 13(1-2):47-53. PubMed ID: 10691291
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Mutational analysis of aspartoacylase: implications for Canavan disease.
    Hershfield JR; Pattabiraman N; Madhavarao CN; Namboodiri MA
    Brain Res; 2007 May; 1148():1-14. PubMed ID: 17391648
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Canavan disease: studies on the knockout mouse.
    Matalon R; Michals-Matalon K; Surendran S; Tyring SK
    Adv Exp Med Biol; 2006; 576():77-93; discussion 361-3. PubMed ID: 16802706
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Aspartoacylase is restricted primarily to myelin synthesizing cells in the CNS: therapeutic implications for Canavan disease.
    Kirmani BF; Jacobowitz DM; Kallarakal AT; Namboodiri MA
    Brain Res Mol Brain Res; 2002 Nov; 107(2):176-82. PubMed ID: 12487123
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Aspartoacylase catalytic deficiency as the cause of Canavan disease: a structural perspective.
    Wijayasinghe YS; Pavlovsky AG; Viola RE
    Biochemistry; 2014 Aug; 53(30):4970-8. PubMed ID: 25003821
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Identification and distribution of aspartoacylase in the postnatal rat brain.
    Klugmann M; Symes CW; Klaussner BK; Leichtlein CB; Serikawa T; Young D; During MJ
    Neuroreport; 2003 Oct; 14(14):1837-40. PubMed ID: 14534431
    [TBL] [Abstract][Full Text] [Related]  

  • 79. SSIEM Award. Aspartoacylase deficiency: the enzyme defect in Canavan disease.
    Matalon R; Kaul R; Casanova J; Michals K; Johnson A; Rapin I; Gashkoff P; Deanching M
    J Inherit Metab Dis; 1989; 12 Suppl 2():329-31. PubMed ID: 2512436
    [No Abstract]   [Full Text] [Related]  

  • 80. Immunohistochemical localization of aspartoacylase in the rat central nervous system.
    Madhavarao CN; Moffett JR; Moore RA; Viola RE; Namboodiri MA; Jacobowitz DM
    J Comp Neurol; 2004 May; 472(3):318-29. PubMed ID: 15065127
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.